stockportfolio.pro
IQVIA Holdings Inc. (IQV)
Healthcare · Diagnostics & Research · NYSE
IQVIA Holdings Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.88B | $9.74B | $10.41B | $11.09B | $11.36B | $13.87B | $14.41B | $14.98B | $15.40B | $16.31B |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $72.00M | $1.28B | $259.00M | $191.00M | $279.00M | $966.00M | $1.09B | $1.36B | $1.37B | $1.36B |
| Net margin | 1.0% | 13.1% | 2.5% | 1.7% | 2.5% | 7.0% | 7.6% | 9.1% | 8.9% | 8.3% |
Source: IQVIA Holdings Inc. SEC filings (10-K). 15 years of history available in the interactive view.
What growth is priced into IQV stock?
At today's market cap of $31.09B, IQVIA Holdings Inc. is priced for free-cash-flow growth of about 3.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $2.05B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 8.8%/yr over the last five fiscal years and revenue 7.5%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 15 years of IQVIA Holdings Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track IQV in your portfolio →
IQVIA Holdings Inc. financial history by metric
About IQVIA Holdings Inc.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
IQVIA Holdings Inc. — frequently asked questions
What is IQVIA Holdings Inc.'s revenue?
IQVIA Holdings Inc. (IQV) reported revenue of $16.31B for fiscal year 2025, up 5.9% from the prior year, according to its SEC filings.
Is IQVIA Holdings Inc. profitable?
Yes. IQV earned net income of $1.36B in fiscal 2025, a net margin of 8.3%.
What is IQV's P/E ratio?
IQVIA Holdings Inc. trades at a price-to-earnings ratio of about 23.1 based on the latest data in our nightly-refreshed cache.
How fast is IQVIA Holdings Inc. growing?
IQV's revenue grew at roughly 7.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does IQVIA Holdings Inc. have?
As of fiscal year 2025, IQV carried roughly $13.88B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is IQVIA Holdings Inc.'s market cap?
IQVIA Holdings Inc. (IQV) has a market capitalization of about $31.09B, based on the latest data in our nightly-refreshed cache.
When does IQVIA Holdings Inc.'s fiscal year end?
IQV's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into IQV stock?
At today's market cap of $31.09B, IQVIA Holdings Inc. is priced for free-cash-flow growth of about 3.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $2.05B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 8.8%/yr over the last five fiscal years and revenue 7.5%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from IQVIA Holdings Inc.'s official SEC filings (10-K and 10-Q), covering 15 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.